XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Subscribe To Our Newsletter & Stay Updated
